Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 16/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626809 | 0.94 | QPCT (0.44) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1178679 | 0.88 | — | — | |
| Bromide SCHEMBL6369678 | 0.86 | CYP19A1 (0.41) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL329374 | 0.82 | ALDH1A1 (0.46) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8591844 | 0.80 | QPCT (0.43) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL16268073 | 0.80 | QPCT (0.47) | QPCT | |
| SCHEMBL1011992 | 0.78 | TBXAS1 (0.43) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL9822957 | 0.78 | TBXAS1 (0.43) | QPCTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14416003 | 0.77 | MAPK13 (0.33) | QPCTCYP11B1CYP11B2 | |
| SCHEMBL19184634 | 0.77 | MAPK13 (0.33) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV BARCELONA (ES) | 2026-04-02 | — | — | US | disclosed |
| CN-110234675-A | Rapidly-curable composition epoxy resin for fiber-matrix semi-finished product | 雷可德公司 | 2019-09-13 | — | — | CN | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9610368-B2 | Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same | PROBIODRUG AG (DE) | 2017-04-04 | — | — | US | disclosed |
| US-9610368-B2 | Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same | PROBIODRUG AG (DE) | 2017-04-04 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-0618907-B1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | BRITISH TECH GROUP INT (GB) | 1999-04-28 | — | — | EP | disclosed |
| CN-1037511-C | Therapeutic agents | BOOTS CO PLC (GB) | 1998-02-25 | — | — | CN | disclosed |
| US-5547972-A | 1-(ARLALKYLAMINOALKYL) IMIDAZOLE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1996-08-20 | — | — | US | disclosed |
| CN-1096781-A | The therapeutical agent that contains 1-(aralkyl-aminoalkyl) imidazolium compounds | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
| WO-1993013075-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | QPCT 189/4885CYP19A1 1629/4885CYP11B1 1991/4885 |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | MAPT, SLC10A1, REN | QPCT 3498/4885CYP19A1 998/4885CYP11B1 17/4885 |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE2, BACE1, GLS2 | QPCT 12/4885CYP19A1 1514/4885CYP11B1 84/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | QPCT 4052/4885CYP19A1 1489/4885CYP11B1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.